QNRX: Several Recent Milestones
The FDA recently granted QRX003 Orphan Drug Designation for the treatment of NS. The European Medicines Agency had granted Orphan Drug...
191 Views
QNRX: Recent FDA & EMA Designations for QRX003 Potentially Could Accelerate Timeline
The FDA recently granted QRX003 Rare Pediatric Disease (RPD) Designation for the treatment of NS. The European Medicines Agency earlier had...
164 Views
QNRX: With Clinical Activities Expanding, QNRX Expects Cash Runway Into 2Q26
In Dec. 2024, Quoin received FDA clearance to initiate a new investigator led whole-body clinical study for QRX003, which will evaluate the...
205 Views
QNRX: More Positive Data Supporting Efficacy of QRX003 for NS Campaign to Raise Awareness of the Disease
There are no approved NS treatments currently & Quoin is optimistic that QRX003 can become the first. The overall patient population is...
197 Views
QNRX: Assessing QRX003 For Multiple Conditions Opening International Netherton Syndrome Clinical Sites
With a strategy to design products to treat multiple indications, QNRX intends to study QRX003 for several conditions & build a database...
248 Views